Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Matthew Snape is a guest on Sierra Leone's radio programme Pikin to Pikin Tok.

Matthew discusses the work of the Department's vaccine group on Ebola vaccines on 'Pikin to Pikin Tok' (which means child to child talk in the local language Krio), a radio series launched during the Ebola crisis. You can listen to the programme here.

The UK child rights agency 'Child to Child' and their partner in Sierra Leone, 'the Pikin to Pikin movement' were running a project in the east of Sierra Leone (in the impoverished Kailahun region where the first case of Ebola was reported) since 2011. This project aimed to enhance children's social, literacy, numeracy and life skills, but the Ebola crisis meant that the NGO's work, which required children to come together in groups, had to stop due to the health risk such gatherings would create.

'Child to Child' decided to turn to radio and commissioned radio producer Penny Boreham, who also works for BBC World Service, to produce the programmes about staying healthy during the crisis and its aftermath.

The radio project, which broadcasts Storytime programmes, music programmes and special programmes like this one on the new Ebola vaccines, is funded by Comic Relief and presented by Sierra Leonean storyteller, Usifu Jalloh.

Similar stories

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

University of Oxford launches new public awareness campaign for Neurodevelopmental Disorders

The Department of Paediatrics at the University of Oxford today announces the launch of Genes, Brains, and Breakthroughs, a new educational campaign designed to raise public awareness and understanding of neurodevelopmental disorders through a series of accessible, family-informed video resources.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

University of Oxford and Serum Institute of India Agree Licence to Advance the Next-Generation Multi-Stage Malaria Vaccine Candidate Component R78C

The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, which has been developed by the Draper Lab in the Department of Paediatrics, and is based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.

Magdalen College lit up for Rare Disease Day

Magdalen College Chapel was lit up in the colours of Rare Disease Day last week, as part of the global Chain of Lights initiative.

New clinical trials begin in Burkina Faso

Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/​Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.